Stryker Co. (NYSE:SYK) Shares Sold by Baldwin Wealth Partners LLC MA

Baldwin Wealth Partners LLC MA decreased its position in shares of Stryker Co. (NYSE:SYK) by 1.2% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 9,345 shares of the medical technology company’s stock after selling 110 shares during the period. Baldwin Wealth Partners LLC MA’s holdings in Stryker were worth $3,365,000 as of its most recent SEC filing.

A number of other institutional investors have also modified their holdings of SYK. Zhang Financial LLC lifted its holdings in shares of Stryker by 55.0% during the fourth quarter. Zhang Financial LLC now owns 114,889 shares of the medical technology company’s stock worth $41,366,000 after purchasing an additional 40,784 shares during the period. Dale Q Rice Investment Management Ltd acquired a new position in shares of Stryker during the 4th quarter worth $587,000. PFW Advisors LLC acquired a new stake in shares of Stryker in the fourth quarter valued at approximately $1,350,000. Traynor Capital Management Inc. acquired a new position in shares of Stryker in the fourth quarter worth $324,000. Finally, Parnassus Investments LLC purchased a new position in Stryker in the 3rd quarter valued at about $762,798,000. 77.09% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several research firms have recently issued reports on SYK. Morgan Stanley upgraded Stryker from an “equal weight” rating to an “overweight” rating and raised their price objective for the stock from $370.00 to $445.00 in a report on Monday, December 2nd. Canaccord Genuity Group lifted their price target on Stryker from $360.00 to $400.00 and gave the company a “buy” rating in a report on Wednesday, October 30th. StockNews.com lowered shares of Stryker from a “buy” rating to a “hold” rating in a report on Wednesday, January 22nd. Wells Fargo & Company upped their price target on shares of Stryker from $405.00 to $427.00 and gave the stock an “overweight” rating in a research report on Wednesday, December 11th. Finally, Robert W. Baird lifted their price target on shares of Stryker from $378.00 to $405.00 and gave the company an “outperform” rating in a report on Wednesday, October 30th. Five research analysts have rated the stock with a hold rating and seventeen have given a buy rating to the stock. According to data from MarketBeat.com, Stryker presently has an average rating of “Moderate Buy” and a consensus target price of $405.80.

Stryker Stock Up 0.2 %

SYK stock opened at $395.27 on Monday. The firm has a fifty day moving average price of $376.11 and a two-hundred day moving average price of $361.15. The company has a debt-to-equity ratio of 0.66, a current ratio of 1.91 and a quick ratio of 1.22. Stryker Co. has a 1-year low of $310.74 and a 1-year high of $399.76. The firm has a market cap of $150.68 billion, a price-to-earnings ratio of 42.35, a PEG ratio of 2.68 and a beta of 0.95.

Stryker (NYSE:SYK) last issued its earnings results on Tuesday, October 29th. The medical technology company reported $2.87 EPS for the quarter, beating analysts’ consensus estimates of $2.77 by $0.10. The company had revenue of $5.49 billion during the quarter, compared to the consensus estimate of $5.37 billion. Stryker had a return on equity of 23.07% and a net margin of 16.34%. Stryker’s quarterly revenue was up 11.9% compared to the same quarter last year. During the same period in the previous year, the firm posted $2.46 earnings per share. Research analysts predict that Stryker Co. will post 12.06 EPS for the current year.

Stryker Increases Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Friday, January 31st. Investors of record on Tuesday, December 31st will be given a $0.84 dividend. The ex-dividend date is Tuesday, December 31st. This is an increase from Stryker’s previous quarterly dividend of $0.80. This represents a $3.36 annualized dividend and a yield of 0.85%. Stryker’s dividend payout ratio (DPR) is currently 36.01%.

Insider Buying and Selling at Stryker

In other Stryker news, CEO Kevin Lobo sold 57,313 shares of the firm’s stock in a transaction dated Thursday, November 7th. The shares were sold at an average price of $368.70, for a total transaction of $21,131,303.10. Following the transaction, the chief executive officer now owns 100,027 shares of the company’s stock, valued at approximately $36,879,954.90. This trade represents a 36.43 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. 5.90% of the stock is currently owned by company insiders.

About Stryker

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.